The new investment will go towards the areas of cancer, inherited diseases, and infectious diseases, with an initial focus on pediatric cancer.
RXi Pharmaceuticals this week released data from a phase I trial of its dermal anti-scarring drug RXI-109, showing that the compound was safe and well-tolerated.
By a GenomeWeb staff reporter
By Monica Heger
In PLOS this week: RNA-seq, ChIP-seq to determine metformin response; array-based approach to detect protozoa in blood; and more.
Fast Company takes a look at startups in the nutrigenomic space that aim to offer personalized diet advice.
In a glamorous event, the Breakthrough Foundation gave out more than $25 million in prizes to researchers.
Immunotherapy might treat cancer, but it also appears to come with a risk of a number of side effects, the New York Times reports.